Previous studies have shown that the deletion of PTPN2 in tumor cells can enhance anti-tumor immunity by promoting IFN/JAK/STAT-1 signaling to drive T cell recruitment and MHC-I-dependent antigen presentation6,10. This evidence concerns the gene IFNA1 and neoplasm.